CVE-2026-75524mediumCWE-367

CVE-2026-75524: medium-severity vulnerability in open-reception appointment-booking-software

OpenReception: race condition in add-to-tunnel and create-new-client allows overlapping appointments for one agent

Published · Updated

Follow this CVE+ Monitor appointment-booking-software

E-mail alert when it lands in KEV, gets a public PoC or its score goes up.

13Vexday Risk Score

No sign of exploitation. No public exploitation artifact known so far.

ssvc Trackcvss 5.4epss 0.3%
OpenReception's appointment booking software provides an end-to-end encrypted appointment booking platform. Prior to version 2.2.2, an attacker overbooks an agent, placing multiple appointments into a single time slot that the system is designed to keep exclusive. The number of overlapping appointments equals the number of concurrent requests, and one booking token is enough because the token is consumed after the insert. This results in the integrity of the booking-calendar breaking and availability being denied to other clients. This issue has been patched in version 2.2.2.
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:L
Affected products
open-reception · appointment-booking-software
Related CVEs — open-reception appointment-booking-software

In the same product, most dangerous first.

CVE-2026-54460CRITICALOpenReception: Unauthenticated WebAuthn passkey injection via `POST /api/auth/passkeys` leads to account takeoverEPSS 0.7%CVE-2026-48085CRITICALOpenReception has unauthenticated GLOBAL_ADMIN account creation post-bootstrapEPSS 0.6%CVE-2026-48087CRITICALOpenReception: WebAuthn passkey injection allows account takeoverEPSS 0.6%CVE-2026-48079HIGHOpenReception's logout page clears local access_token before server-side revocation, leaving duplicated tokens valid until expiryEPSS 0.5%CVE-2026-48080HIGHOpenReception's tenant detail endpoint discloses live PostgreSQL connection string, superuser-scoped in the tested official deploymentEPSS 0.5%CVE-2026-48086CRITICALOpenReception: Tenant admin self-promotes to GLOBAL_ADMINEPSS 0.4%